Captor Therapeutics ® Investor Relations

      Investor Relations

      Admission of shares and rights to shares to trading

      Publication date: 2021-04-15
      Number: RB ESPI 3/2021

      Current report no. 3/2021

      Date of preparation: 15 April 2021

      Subject: Admission of shares and rights to shares to trading

      Legal basis: § 17 sec. 1 point 2 of the Regulation of the Minister of Finance dated 29 March 2018 on current and periodical information disclosed by issuers of securities and conditions for recognition as equivalent of information required by the provisions of law of a country other than a member state

      The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the “Company”) informs that on 15 April 2021 the Company became aware of the adoption by the management Board of Giełda Papierów Wartościowych w Warszawie S.A. (“WSE”) of Resolution no. 406/2021 dated 15 April 2021 to admit to trading on the WSE primary market the following securities of the Company:

      1. 1,757,075 series B ordinary bearer shares;
      2. 82,449 series C ordinary bearer shares;
      3. 97,051 series D ordinary bearer shares;
      4. 26,925 series F ordinary bearer shares;
      5. 871,500 series G ordinary bearer shares, provided that the increase of the share capital of the Company as a result of issuance of such shares is registered;
      6. 52,354 series H ordinary bearer shares;
      7. 9,082 series I ordinary bearer shares;
      8. 84,143 series J ordinary bearer shares; and
      9. 871,500 rights to series G ordinary bearer shares,

      with a nominal value of PLN 0.10 each.

      The resolution enters into force as of the date of adoption thereof.